Electronic common technical documents
The deadline for the much discussed , mandatory electronic Common Technical Docment (eCTD), has already arrived—January 1, 2008—andFDA's Center for Drug Evaluation and Research (CDER) now expects all investigational new drug and marketing applications to be submitted in electronic format. Companies unable to meet eCTD requirements don't have too many options. They can, a) resort to submitting applications in paper CTD format, using "temporary hardship" as an excuse, or b) outsource the work. Both solutions carry the possibility of delay, distraction, increased costs, and diminished prospects for success.The more practical—and longterm— solution is to implement an eCTD publishing system in-house. Companies pursuing this option should seek to gain more than just eCTD compatible output. Getting an eCTD ready goes beyond the ability to produce PDF files with the appropriate hierarchy and XML backbone for navigation. The life cycle management of the product as a whole is critical in managing changes and requests for information from global agencies. Document management and document changes are also tied to product registrations and submission life cycles. An integrated solution is ideal for managing the document, submission, and product life cycles on an international level and should include the following information:
The development of a global regulatory strategy document (GRSD) should be on top of a company's "to do list" in 2008. This document provides a gameplan for regulatory strategy to achieve a company's objectives in marketing and supporting a drug. The GRSD include information such as:
There are no guidelines or regulations that explain how a regulatory strategy should be compiled. However, several industry organizations have resources and conferences that outline what should be included for pharmaceuticals and biologics in a regulatory strategy.
Companies should also develop a risk minimization action plan (RiskMAP) either as part of a more diverse GRSD or as a separate initiative to meet current regulatory guidelines. A RiskMAP includes both risk assessment and risk minimization. A RiskMAP strategy should be multidimensional and address various methods of minimizing risk, including how to reduce and control potential drug misuse, abuse, or overall risk based on the target population's demographics and contraindications. Specifically, a RiskMAP strategy should outline the following and provide the corresonding benefits: